49 results about "Aortic aneurysm" patented technology

The invention discloses a screening method of a protein marker combination, which is used for risk prediction of abdominal aortic aneurysm or ruptured abdominal aortic aneurysm, and optimizes the stability of a protein expression profile by constructing an initial protein expression profile; screening differential expression proteins by adopting statistical analysis, and preliminarily locking candidate proteins remarkably associated with a disease endpoint based on survival analysis or a risk regression model; performing cross validation by combining a sparse constraint algorithm and a nonlinear feature selection algorithm, and extracting a robust core marker; the independent contribution degree of each marker is evaluated through the standardized weight, and finally the optimal protein combination for disease prediction or diagnosis is determined. According to the method, six core proteins obtained through multi-algorithm cross screening can be detected in serum, multivariable logistic regression and external verification set performance both show good robustness, and an aorta protein fingerprint feature set which can be popularized and explained is formed.

The application belongs to the technical field of biological medicine, and relates to application of a CXCL14 inhibitor in preparation of a drug for preventing or treating abdominal aortic aneurysm of a patient. The inhibitor effectively eliminates the gender difference of abdominal aortic aneurysm by specifically blocking the combination of CXCL14 and its receptor CXCR4, significantly reduces aortic macrophage infiltration and PDGFRA + macrophage accumulation in the progress of abdominal aortic aneurysm, reduces the degree of collagen degradation and elastic fiber damage, and thus inhibits the pathological progress of abdominal aortic aneurysm. The application provides a new target and drug combination for precise treatment of male abdominal aortic aneurysm, and has clear clinical application value.

The invention discloses an application of methylene blue in preparation of drugs for preventing and treating aortic dissection and aortic aneurysm, which proves that after methylene blue is orally taken in an aortic aneurysm mouse model, expansion of aortic diameter can be inhibited and occurrence rate of aortic dissection and aortic aneurysm can be reduced after methylene blue is given. Abnormal aorta dilatation of mice and disorder and fracture of elastic fibers caused by BAPN water drinking are improved. Therefore, the death rate of the BAPN-induced aortic dissection and aortic aneurysm mice can be reduced and the disease progress of the aortic dissection and aortic aneurysm can be delayed by giving the methylene blue, so that the expansion condition of the aorta of the mice is improved and the survival rate is increased.

The invention relates to the technical field of biological medicines, and particularly relates to a method for researching the influence of silencing or inhibiting a UBE2G1 gene on the growth of abdominal aortic aneurysm by constructing a UBE2G1 gene function deletion mouse model. Results show that silence or inhibition of UBE2G1 gene expression can inhibit growth of abdominal aortic aneurysm, alleviate destruction of elastic fibers of arterial tissues, reduce levels of inflammatory factors such as TNF-alpha, IL-1beta and IL-6 in a body and inhibit polarization of macrophage M1. According to the invention, a certain theoretical basis is provided in the aspect of treatment of abdominal aortic aneurysm by means of biotechnology, and the UBE2G1 gene (or protein) can be used as a drug target for treatment of abdominal aortic aneurysm.

The invention belongs to the technical field of gene therapy and biological medicine, and particularly provides application of leucine in preparation of a medicine for preventing and / or treating aortic aneurysm. The leucine is independently used or is combined with other medicines for preventing and / or treating aortic aneurysm. The activity of GLUD1 is enhanced through leucine, so that conversion of Glu to alpha-KG is promoted, degradation of Glu is promoted, namely, the Glu level is reduced by enhancing degradation of Glu, and aortic aneurysm is improved. In a Glu metabolic network, Gln can be converted into Glu under the action of glutaminase 1 (GLS1), so that the generation of Glu is inhibited by inhibiting the activity of GLS1, and the effect of preventing and / or treating aortic aneurysm is achieved.

The invention provides an abdominal aortic aneurysm early prediction model construction method, system and device and a medium. According to the method, a balanced research queue is constructed through fusion of multi-modal data (ultrasonic images, biochemical indexes and lipidomics) and tendency score matching, so that the accuracy of early risk identification of the abdominal aortic aneurysm and the model robustness are remarkably improved; furthermore, on the basis of a risk migration strategy, the discrimination capability of the complex deep learning model is migrated to a simplified logistic regression model which only needs a simplest lipid feature set and basic demographic information, so that high prediction performance is maintained, model lightweight, parameter immobilization and clinical interpretability are realized, the detection cost and the operation complexity are greatly reduced, and the detection efficiency is improved. A high-precision risk prediction technology can be conveniently deployed in a basic medical scene, and finally an abdominal aortic aneurysm early screening solution with high precision, high interpretability and wide applicability is formed.

The utility model discloses a covered stent capable of being used for treating aortic aneurysm diseases, which relates to the technical field of medical instruments and comprises a self-expanding stent, a clamping piece is fixedly connected to the waist line position of an expanding portion of the self-expanding stent, and the clamping piece is made of super-elastic memory alloy. A mode of combining radial force anchoring and structure anchoring is adopted, a part of an anchoring piece is changed into a clamping piece from a traditional barb, the stent moves downwards after arriving at a designed position, the anchoring piece is unfolded and fixed on small blood vessels on two sides, meanwhile, the upper end of the clamping piece is self-expanded and unfolded, double anchoring is carried out, displacement of the stent is avoided, and the stability of the stent is improved. A self-expanding stent is adopted for supporting and an elastic clamping piece and a native blood vessel are clamped for fixing, additional damage is avoided, meanwhile, double-layer polyurethane films are adopted for covering, the anti-leakage capacity is improved while the flexibility is guaranteed, the blood vessel can be prevented from being damaged, and stable support is provided.

The invention relates to an abdominal aortic aneurysm filling system and treatment system, the filling system comprises a filling assembly, the filling assembly comprises at least two filling blocks, each filling block adopts shape memory polymer foam, and each filling block has a compressed loading state and an implantation state of expanding at a preset position; the interventional catheter is used for containing the filling assembly to implement interventional delivery, and the filling blocks are sequentially arranged in the extending direction of the interventional catheter in the loading state; the connecting shaft is arranged in the interventional catheter in a sliding mode, the far-end portion of the connecting shaft sequentially penetrates through and is connected with the filling blocks so as to carry the filling blocks to be released from the far-end side of the interventional catheter into the abdominal aortic aneurysm, and the far-end portion of the connecting shaft is configured to be spirally wound around a space axis in a pre-shaping mode. The surgical operation process is simplified, the filling blocks are arranged relatively orderly after being released and expanded, the space filling rate is high, and the surgical treatment effect is further improved.

Embodiments described herein relate to a shunt for treating an aortic aneurysm and a robotic insertion system for implanting the shunt. In some embodiments, the shunt may include a central portion, an arterial sealing structure, and a venous sealing. In some embodiments, the venous sealing structure may have a lateral length in its deployed configuration, and the arterial sealing structure having a lateral length in its deployed configuration that is greater than the lateral length of the venous sealing structure. The shunt may be advanced robotically in a delivery configuration through a venous puncture site of a vein to access an arterial puncture site of the artery, and then deployed, thereby enabling blood flow through the shunt from the artery to the vein.

The invention belongs to the technical field of medicines, and particularly relates to a prodrug for supplementing NAD < + >, which is an NAMPT agonist YB8, and an application of the prodrug in prevention and treatment of abdominal aortic aneurysm. The invention discloses a prodrug YB8 capable of specifically activating nicotinamide phosphoribosyltransferase (NAMPT), and the prodrug YB8 can effectively improve the level of NAD + (nicotinamide adenine dinucleotide) in cells, so that the degenerative change of a vascular structure is slowed down, the purposes of protecting blood vessels and treating abdominal aortic aneurysm are achieved, and the YB8 is proved to be used as a specific activator of NAMPT for the first time. The multi-target treatment effect is achieved by improving the blood vessel NAD + level; the discovery provides a brand new strategy for the drug treatment of abdominal aortic aneurysm, and the treatment advantages are as follows: ultrasonic imaging proves that the tumor progress can be obviously inhibited; the discovery lays an important foundation for developing clinical treatment of abdominal aortic aneurysm based on NAD + metabolism regulation.

The invention discloses application of a biomarker in preparation of a product for diagnosing abdominal aortic aneurysm, a kit and a use method, the biomarker has the advantages of high sensitivity, strong specificity and high accuracy, and the detection method is simple and rapid and has important significance in early screening of abdominal aortic aneurysm. The biomarker is any one of the following exosome proteins or a combination thereof: fibrinogen beta chain, fibronectin, lysosome related membrane glycoprotein 2 and histone H4.

A robotic surgical method for repair of an infrarenal aortic aneurysm with an aneurysm sac in an aorta of a patient includes introducing at least one arm and a camera of a robotic surgical system into designated ports of the patient. Then, a graft is attached to a proximal wall of the aorta. The aneurysm sac is decompressed by inflating an intravascular balloon and initiating flow in an arteriovenous circuit. Anterior posterior walls of the aneurysm sac are stapled and the robotic incisions are closed. A method for inserting a conduit includes deploying an intimal umbrella, partially expanding an expandable graft, deploying an adventitial umbrella, and fully inflating the expandable stent.

The invention relates to application of a JAML gene in preparation of an abdominal aortic aneurysm resisting medicine, and belongs to the technical field of biological medicine. The nucleotide sequence of the JAML gene is as shown in SEQ ID No.1. The application of the JAML gene in preparation of the abdominal aortic aneurysm resisting medicine comprises the following two aspects: (1) applying the JAML gene as an action target to preparation of the abdominal aortic aneurysm resisting medicine; and (2) applying the JAML gene as an action target to screening of drugs for resisting abdominal aortic aneurysm. According to the invention, a gene knockout mouse of which the smooth muscle specifically knockout JAML is constructed, and then the mouse abdominal aortic aneurysm model is constructed by subcutaneously pumping AngII, so that the morbidity of abdominal aortic aneurysm can be obviously reduced after the JAML gene is knocked out; therefore, a theoretical basis is provided for preparing or screening drugs or preparations for inhibiting smooth muscle cell JAML gene expression as alternative drugs or preparations for resisting abdominal aortic aneurysm.

The invention provides an application of GPR146 in treatment of abdominal aortic aneurysm. The application proves that the morbidity and mortality of the aortic aneurysm can be effectively reduced by knocking down or knocking out the GPR146; reducing the diameter of the abdominal aorta; the conditions of artery lumen stenosis, vascular structure disorder, remodeling and elastic fiber fracture are reduced. The application provides a new treatment approach beyond surgery for the clinical problem of abdominal aortic aneurysm treatment.

The invention relates to the technical field of medical instruments, in particular to an abdominal aortic aneurysm cavity support auxiliary positioning device. An inner tube and a positioning assembly are coaxially arranged in the outer sheath tube in a sleeving manner; the outer sheath tube is connected with the near end of the inner tube, so that the relative positions of the outer sheath tube and the inner tube can be kept consistent; the positioning assembly is arranged on the periphery of the inner tube in a sleeving mode and can slide between the outer sheath tube and the inner tube. A penetrating through hole is formed in the center of the inner tube, and a guide wire can penetrate through the penetrating through hole and slide in the inner tube. The auxiliary positioning device for the abdominal aortic aneurysm cavity support is simple in structure, easy and convenient to operate and capable of effectively assisting in positioning a main body support short iliac branch opening in an abdominal aortic aneurysm cavity, the butt joint efficiency of the main body support short iliac branch and an iliac branch extension support is improved, the operation time is shortened, the operation risk is reduced, and ray damage is reduced.

The invention relates to application of an Arteridin gene as a biomarker in preparation of a product for auxiliary diagnosis of abdominal aortic aneurysm, clinical specimens and animal experiments find that the expression of Arteridin in occurrence of abdominal aortic aneurysm is remarkably increased, which indicates that Arteridin can be used as the biomarker for auxiliary diagnosis of abdominal aortic aneurysm; the invention also relates to a product for down-regulating the expression of Arterin and an application of the product in preparation of drugs for treating abdominal aortic aneurysm, the product comprises siRNA and shRNA of a targeted Arterin gene and AAV for coding the sequence of the shRNA, and after specific knockdown of Arterin by smooth muscle cells is realized, in an Elatase-induced abdominal aortic mouse model, the expression of Arterin is reduced, and the expression of Arterin is reduced. The diameter of the aneurysm is reduced, the occurrence rate is reduced, the elastin destruction degree is reduced, the expression quantity of vascular remodeling genes MMP2 and MMP9 is reduced, and the difference is obvious compared with that of a control group; the result shows that Arteridin is expected to become a target spot for treating abdominal aortic aneurysm.

The invention discloses an application of Anti-TSLP (Transcriptional Stem Like Protein) in prevention or treatment of abdominal aortic aneurysm. The Anti-TSLP is an anti-TSLP (Transcriptional Stem Like Protein) monoclonal antibody. The application of Anti-TSLP as a monoclonal antibody drug in prevention or treatment of abdominal aortic aneurysm is found for the first time. By intraperitoneal injection of Anti-TSLP and neutralization of TSLP pro-inflammatory cytokines, macrophage M1 / M2 phenotype can be effectively regulated, macrophage-mediated inflammatory response can be regulated and controlled, abdominal aortic aneurysm can be relieved, and a potential treatment scheme is provided for precise treatment of patients with clinical abdominal aortic aneurysm.

The invention provides a medical implantation device for anastomosis of the proximal end and the distal end of the aorta. The device is intended to facilitate the connection of the aorta to the device, the two ends of which are one specification smaller than the aorta. The device is provided with grooves and protrusions at about 8 mm from both ends, specifically designed to assist the application of suture loops to tighten the aorta and block blood flow between the device and the aorta. The design of the device aims to simplify the anastomosis operation process, reduce the time and operation skill requirements required by surgeons for performing the operation, and improve the overall safety and effectiveness of the anastomosis operation.

A robotic surgical method for repairing a subrenal aortic aneurysm having an aneurysm sac in an aorta of a patient includes introducing at least one arm of a robotic surgical system and a camera into a specified portal of the patient. A graft is then attached to the proximal wall of the aorta. The aneurysm balloon is decompressed by inflating the intravascular balloon and inducing flow in the arteriovenous circuit. The anterior and posterior walls of the aneurysm sac are stapled and the robotic incision is closed. A method for inserting a tube includes deploying an intimal umbrella, partially expanding an expandable graft, deploying an outer membrane umbrella, and fully inflating the expandable stent.

1. The name of the design product: covered stent (180 degree opening). 2. The use of the design product: for treating aortic aneurysm, dissection or vascular rupture and other lesions, repairing the diseased blood vessels. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best shows the design points: perspective view.

The invention relates to the technical field of medical instruments, and discloses a form-adaptive aortic dissection false cavity or aneurysm cavity thrombosis promoting embolism device which comprises a double-layer metal grid spindle-shaped skeleton of a hollow structure. Comprising a connecting point at the upper end and the lower end and an arc-shaped side face connected between the two points. The isolating membrane is located between the double-layer metal grid fusiform skeletons, and the double-layer metal grid fusiform skeletons are small in size after being compressed, can be quickly released and automatically adapt to the shape of an aortic dissection false cavity or an aneurysm cavity, so that the aneurysm cavity or the false cavity is fully blocked, and thrombosis of the aneurysm cavity or the false cavity is promoted. The device is simple in structure, convenient to operate, capable of adapting to the shape of an interlayer false cavity to be fully filled, good in blood flow isolation effect, capable of rapidly promoting thrombosis and remodeling of the false cavity, free of reverse compression of a true cavity and capable of being applied to occasions where embolism needs to be conducted on abdominal aortic aneurysm cavities and other branch arteries.

The application discloses application of CCR6 gene in preparation of an anti-abdominal aortic aneurysm medicine and belongs to the technical field of medicines. The application selects CCR6-siRNA interference technology, constructs an adeno-associated virus expression vector, inhibits expression of a mouse CCR6 gene, and constructs a mouse abdominal aortic aneurysm model by subcutaneous pumping of angiotensin II, finds that inhibition of the CCR6 gene can significantly reduce the incidence of abdominal aortic aneurysm and inhibit the occurrence and development of abdominal aortic aneurysm, and provides a theoretical and experimental basis for preparation and screening of a medicine or preparation for inhibiting expression of the CCR6 gene as a candidate medicine or preparation for resisting abdominal aortic aneurysm. The application prepares an adeno-associated virus for inhibiting the CCR6 gene, and finds that inhibition of the CCR6 gene can significantly inhibit the occurrence and development of abdominal aortic aneurysm by injecting the adeno-associated virus for inhibiting the CCR6 gene into a mouse tail vein.

The application discloses application of Danshen-Gegen vesicle-like nanoparticles and belongs to the technical field of biological medicine. The Danshen-Gegen vesicle-like nanoparticles (SPVLNs) are extracted and purified from Danshen-Gegen decoction liquid by using a differential super-high-speed centrifugation method. The SPVLNs have good blood compatibility. When the SPVLNs are applied to treating abdominal aortic aneurysm, the SPVLNs can obviously relieve thickening of a blood vessel wall, reduce infiltrative cells of an arterial media and an adventitia, improve reduction and fracture of elastic fibers of the blood vessel wall, increase stretchability of the elastic fibers of the blood vessel wall, reduce contents of tissue muscle fibers and collagen fibers, reduce a fibrosis degree of the collagen fibers, obviously improve pathological changes of a mouse abdominal aorta caused by Ang II, and are safe and non-toxic.

The invention provides application of an adeno-associated virus overexpressing CTH in preparation of drugs for extravascular treatment of abdominal aortic aneurysm. When the adeno-associated virus overexpressing CTH is applied to the periphery of abdominal aortic aneurysm, fracture of elastic fibers of abdominal aorta can be reduced, collagen deposition can be reduced, infiltration of macrophages (CD68) can be reduced, secretion of matrix metalloproteinase can be reduced, degradation of extracellular matrixes can be reduced, and occurrence and development of AAA can be relieved.

An endovascular treatment system including branch features for perfusing branch vessels such as the renal arteries, celiac arteries, and mesenteric arteries (e.g., for treating aortic aneurysms).

Compositions and methods for treating oxidative stress, and conditions where oxidative stress contributes to conditions such as diabetes, in a subject by administering an effective amount of cobinamide. Oxidative stress can be caused by, for example, increased levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS) in the patient. Compositions and methods for treating oxidative stress that contributes to diabetes-associated conditions such as cardiac fibrosis, and to aortic aneurysm, lipid or protein oxidation, or DNA damage, in a subject by administering an effective amount of cobinamide.

The application belongs to the technical field of biological medicine and nanomaterials, and particularly relates to a nano system for targeted photothermal-chemotherapy synergistic treatment of abdominal aortic aneurysm as well as a preparation method and application thereof. The system is a mesoporous polydopamine-coated gold nanorod cluster (AuM) nanoparticle co-loaded with one or more traditional Chinese medicine ingredients and modified by c(RGDfK) cyclic peptide. The preparation comprises the following steps: taking chloroauric acid and dopamine hydrochloride as raw materials, synthesizing AuM in the presence of a reaming agent and a template agent by a one-step method; further loading a large amount of drugs in the mesopores to obtain drug-loaded nanoparticles; and finally grafting a targeting peptide on the surface of the nanoparticles to obtain the final product. The system has the characteristics of targeting macrophages and smooth muscle cells, NIR-Ⅱ photothermal conversion and photothermal response drug release. The in-vitro and in-vivo experimental results show that the system can realize local photothermal treatment and precise drug release under NIR-Ⅱ light, and inhibit aortic dilation through various cell behaviors, thereby providing a nano preparation with clinical transformation potential for precise treatment of abdominal aortic aneurysm.

The invention belongs to the field of biological medicines, particularly discloses an application of NiMn-PB in preparation of an abdominal aortic aneurysm protection medicine, and discloses that NiMn-PB can obviously improve degradation of an aortic elastic fibrous layer caused by Ang II treatment and can relieve immune cell infiltration, inflammation release, ferroptosis and angiogenesis in aorta; after Ang II treatment, NiMn-PB is used for intervention, occurrence and development of the abdominal aortic aneurysm induced by Ang II can be relieved, and it is indicated that NiMn-PB can be used for preparing the medicine for relieving the abdominal aortic aneurysm.

This invention belongs to the field of biomedical technology, specifically relating to the application of metabolic markers in the preparation of products for diagnosing abdominal aortic aneurysms. The metabolic markers include 5-δ-hydroxybutylhydantoin, 1-α-amino acid, and PGF. 2α The present invention provides one or more of the following metabolites: D-pyroglutamic acid, nicotinic glucuronide, cysteine ​​glutathione disulfide, or Trp-P-1. Experiments have confirmed that the seven metabolites, alone or in combination, have good specificity and sensitivity as metabolic markers for diagnosing abdominal aortic aneurysms.

There is provided a method and a system for training and using one or more machine learning (ML) models to predict abdominal aortic aneurysm (AAA) growth based on at least one image of a given patient having been previously diagnosed with AAA. Baseline and follow-up images of patients having AAA are received and compared to determine difference in aortic areas, and each baseline image is labelled as showing significant AAA growth or non-significant AAA growth based on the determined differences. Features are extracted from the aortic areas of the baseline images and include one or more of shape features, texture features or deep features. ML models are trained to classify baseline images as showing significant AAA growth or not based on the extracted features. Calcification accumulation in the baseline images is also determined as an indicator of AAA growth.